Acadia Pharmaceuticals (ACAD) Operating Income: 2009-2025
Historic Operating Income for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $35.8 million.
- Acadia Pharmaceuticals' Operating Income rose 12.99% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.9 million, marking a year-over-year increase of 114.66%. This contributed to the annual value of $230.8 million for FY2024, which is 414.52% up from last year.
- According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Operating Income is $35.8 million, which was up 10.45% from $32.4 million recorded in Q2 2025.
- In the past 5 years, Acadia Pharmaceuticals' Operating Income ranged from a high of $153.5 million in Q4 2024 and a low of -$113.0 million during Q1 2022.
- Its 3-year average for Operating Income is $22.3 million, with a median of $30.4 million in 2024.
- Its Operating Income has fluctuated over the past 5 years, first tumbled by 101.73% in 2022, then skyrocketed by 902.21% in 2024.
- Acadia Pharmaceuticals' Operating Income (Quarterly) stood at -$44.7 million in 2021, then declined by 3.15% to -$46.1 million in 2022, then skyrocketed by 175.86% to $34.9 million in 2023, then skyrocketed by 339.28% to $153.5 million in 2024, then grew by 12.99% to $35.8 million in 2025.
- Its Operating Income stands at $35.8 million for Q3 2025, versus $32.4 million for Q2 2025 and $19.3 million for Q1 2025.